OncoMatch/Clinical Trials/NCT06846268
Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
Is NCT06846268 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including ADG126 and Pembrolizumab for locally advanced colorectal cancer.
Treatment: ADG126 · Pembrolizumab — This is a single site, open-label, single-arm phase II study to determine feasibility, tolerability, and preliminary efficacy of neoadjuvant ADG126 and pembrolizumab in stage II or III colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Colorectal Cancer
Disease stage
Required: Stage II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiation therapy
Prior radiation therapy ... for colorectal cancer
Cannot have received: chemotherapy
Prior ... chemotherapy ... for colorectal cancer
Cannot have received: immunotherapy
Prior ... immunotherapy ... for colorectal cancer
Cannot have received: surgery
Prior ... surgery for colorectal cancer
Lab requirements
Blood counts
ANC ≥ 1,500/mcL; Platelets ≥ 100,000/mcL; Haemoglobin ≥ 9 g/dL
Kidney function
Serum creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 60 mL/min for subjects with creatinine > 1.5 x ULN
Liver function
Serum total bilirubin ≤ 1.5 x ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin > 1.5 x ULN. AST and ALT ≤ 2.5 x ULN.
Demonstrate adequate organ function as defined below ... Haematological: ANC ≥ 1,500/mcL; Platelets ≥ 100,000/mcL; Haemoglobin ≥ 9 g/dL. Renal: Serum creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 60 mL/min for subjects with creatinine > 1.5 x ULN. Hepatic: Serum total bilirubin ≤ 1.5 x ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin > 1.5 x ULN. AST and ALT ≤ 2.5 x ULN. Coagulation: INR ≤ 1.5 or PT ≤ 1.5 x ULN; and either PTT or aPTT ≤ 1.5 x ULN. Patients on warfarin may be included on a stable dose with a therapeutic INR < 3.5.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06846268 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage II or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages